Changes in BAI1 and nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 307-314

  Meisen, Walter Hans ^a   Dubin, Samuel ^a   Sizemore, Steven T ^a   Mathsyaraja, Haritha ^a   Thies, Katie ^a   Lehman, Norman L ^a   Boyer, Peter ^a   Jaime Ramirez, Alena Cristina ^a   Elder, J Bradley ^a   Powell, Kimerly ^a   Chakravarti, Arnab ^a   Ostrowski, Michael C ^a   Kaur, Balveen ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ANGIOGENESIS INHIBITOR 1; G PROTEIN COUPLED RECEPTOR; NESTIN; ONCOLYTIC HERPES SIMPLEX VIRUS 34.5ENVE; ONCOLYTIC HERPES VIRUS; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VSTAT 120; ANGIOGENIC PROTEIN; BAI1 PROTEIN, HUMAN; NES PROTEIN, HUMAN; ONCOLYTIC VIRUS; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; BREAST NEOPLASMS; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERO CELL LINE;

ANGIOGENIC PROTEINS; ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; NEOPLASM METASTASIS; NESTIN; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROGNOSIS; VERO CELLS;

EID: 84921507719     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0659     Document Type: Article

References (24)

1. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20.
2. Fidler IJ, Balasubramanian K, Lin Q, Kim SW, Kim SJ. The brain microenvironment and cancer metastasis. Mol Cells 2010;30:93-8.
3. Gonzalez-Angulo AM, Hortobagyi GN. Brain metastases and breast cancer subtypes. Onkologie 2010;33:143-4.
4. Cork SM, Van Meir EG. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med (Berl) 2011;89:743-52.
5. Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA, et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009;69:1212-20.
6. Kudo S, Konda R, Obara W, Kudo D, Tani K, Nakamura Y, et al. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 2007;18:785-91.
7. Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY, Epstein JI, et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007;67:9199-206.
8. Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, et al. Clinical implications for nestin protein expression in breast cancer. Cancer Sci 2010;101:815-9.
9. Apostolou P, Toloudi M, Chatziioannou M, Ioannou E, Papasotiriou I. Cancer stem cells stemness transcription factors expression correlates with breast cancer disease stage. Curr Stem Cell Res Ther 2012;7:415-9.
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
11. Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 2012;20:287-97.
12. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, et al. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 2005;22:47-59.
13. Zabuawala T, Taffany DA, Sharma SM, Merchant A, Adair B, Srinivasan R, et al. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res 2010;70:1323-33.
14. Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, et al. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther 2013;21:1517-25.
15. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
16. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
17. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
18. Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res 2013;19:6404-18.
19. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285-94.
20. Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer 2012;2012:628697.
21. Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, et al. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim 2004;40:14-21.
22. Scott BJ, Kesari S. Leptomeningeal metastases in breast cancer. Am J Cancer Res 2013;3:117-26.
23. Pekmezci M, Perry A. Neuropathology of brain metastases. Surg Neurol Int 2013;4:S245-55.
24. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013;14:64-71.